Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

The U.S. Federal Drug Administration (FDA) has granted Incyclix Bio Fast Track designation for INX-315 to treat ...

In April 2025, the Company announced that the first patient had been dosed in Part 2a of the Phase 2 DENALI clinical trial ( NCT05128825) of azenosertib in patients with Cyclin E1+ platinum-resistant ...

CALGARY, AB / ACCESS Newswire / May 14, 2025 / Valeura Energy Inc. ("Valeura" or the "Company") reports its unaudited financial and operating results for the three month period ended March 31, ...

Calendar of Events, Conference Calls/ Webcasts, Earnings Releases and Operating Results, GlobeNewswire, Oil & Gas Producers | SINGAPORE, May 14, 2025 (GLOBE NEWSWIRE) -- Valeura Energy I ...